Food Biotech’s US$75,000 Second Life

Meati lost the bathwater, but a remarkably well-priced baby has been saved providing food biotech's second life.

Somewhere amid the collapse and attempted revival of US alternative-protein company Meati Foods, a valuable piece of the food-biotech future was left behind: twelve 25,000-litre fermentation tanks, their associated seed systems and a combined 300,000 litres of production capacity.

Boston-based plant-cell specialist Ayana Bio and India’s Zenfold Sustainable Technologies have now acquired the equipment for just US$75,000. Reportedly worth several million dollars, the fermentation assets will be dismantled at Meati’s former Colorado facility, transported to India and returned to productive use, potentially during the first half of 2027.

Meati used fermentation to grow mycelium for meat alternatives. Ayana and Zenfold will repurpose the same equipment to cultivate plant cells capable of producing valuable compounds for food, supplements, medical nutrition and personal care. Initial targets include rosmarinic acid from sage, crocins from saffron, and the eye-health carotenoids zeaxanthin and lutein from marigold.

The potential applications are considerably broader: natural preservatives replacing synthetic additives; stable colours and antioxidants; concentrated nutritional compounds; and reliable alternatives to botanicals affected by climate disruption, contamination, adulteration or volatile harvests. Plant-cell cultivation could eventually unlock useful compounds that remain too scarce or expensive to produce through conventional agriculture.

It is an extraordinary transfer of industrial potential. Meati’s business struggled beneath a high-cost US production model largely built around one consumer proposition. Its new owners will gain a flexible platform on which multiple plant ingredients can be tested, refined and scaled before moving into Zenfold’s existing 100,000-litre bioreactors.

The first food-biotech boom raised hundreds of millions of dollars to build factories around individual products. The second may use those same factories as flexible platforms, producing multiple ingredients, serving multiple markets and bringing new biology to commercial scale considerably faster.

TRENOS SiGINT

SIGNAL

Food biomanufacturing is entering its second industrial cycle.

The first generation built expensive facilities while simultaneously trying to perfect its technology, establish consumer brands and create new markets.

Ayana and Zenfold can begin with industrial capacity already in place. Instead of rebuilding Meati, they can redirect its equipment towards a wider and potentially more valuable range of botanical ingredients.

The failure of the original business has not removed the productive infrastructure. It has released it for a different purpose.

HUMAN FACTOR

Meati required consumers to adopt an unfamiliar meat alternative. Ayana’s plant-cell ingredients can operate inside products people already understand.

Consumers may encounter the technology as a natural preservative, a more consistent colour, an antioxidant or an affordable nutritional compound, without needing to change how they eat.

That dramatically reduces the behavioural burden. Consumers do not have to buy the technology; they only have to value what it improves.

METRICS SNAPSHOT

US$75,000 — ACQUISITION PRICE

Ayana Bio and Zenfold jointly acquired Meati’s core fermentation equipment for a fraction of its reported multimillion-dollar value.

Signal: High-quality biomanufacturing assets are entering the secondary market at distressed prices.

Why it matters: New operators can direct more resources towards developing ingredients and securing customers rather than constructing equipment from scratch.

300,000 LITRES — TOTAL CAPACITY

The acquisition includes twelve 25,000-litre fermenters and their associated seed systems.

Signal: This is commercially meaningful infrastructure rather than a laboratory-scale operation.

Why it matters: Ayana can test multiple plant-cell lines at intermediate scale before committing them to much larger production vessels.

12 × 25,000 LITRES — FLEXIBLE PRODUCTION

Multiple vessels allow different cell lines, ingredients and production processes to be developed independently.

Signal: The facility is not limited to one ingredient or consumer product.

Why it matters: Capacity can be allocated across natural preservatives, colours, antioxidants and nutritional bioactives—or made available to other plant-cell companies.

100,000 LITRES — NEXT SCALE AVAILABLE

Zenfold already operates four 100,000-litre bioreactors in India.

Signal: The acquired tanks provide the missing bridge between pilot development and large-scale manufacturing.

Why it matters: Promising ingredients can move through testing, process refinement and commercial production within the same manufacturing partnership.

H1 2027 — TARGET OPERATING DATE

The equipment is expected to be relocated and operating in India during the first half of 2027.

Signal: Ayana could gain substantial pilot and production capacity without waiting years for a purpose-built facility.

Why it matters: Speed to commercial scale may become as important as the original scientific discovery.

LONG PLAY

Ayana and Zenfold are not buying Meati’s business model. They are acquiring the industrial bridge needed to move plant-cell ingredients from laboratory development into commercial production.

The 25,000-litre fermenters will allow Ayana to test each cell line, improve yields and confirm production consistency before moving into Zenfold’s 100,000-litre vessels. That could eliminate years otherwise spent designing and constructing intermediate-scale capacity.

The facility can also support a much broader portfolio than Meati’s mycelium meat proposition. One vessel might cultivate sage cells for a natural preservative; another saffron cells for crocins; another marigold cells for nutritional carotenoids. Pilot capacity will also be offered to other plant-cell companies.

For food manufacturers, this could create more reliable supplies of botanical compounds that are currently expensive, seasonal or exposed to crop failure, contamination and adulteration. Controlled cultivation may also produce higher concentrations of desirable bioactives than conventional plants.

Meati built the tanks to manufacture meat alternatives. Their new owners may use them to help establish an entirely broader botanical ingredient industry and reach commercial production far sooner than if they had started with an empty factory.

ENDS: